Intervention with PF-04691502 enhances cognitive performance and reduces amyloid-β accumulation in a mouse model, suggesting potential for AD treatment.
Key Points
PF-04691502 treatment improved spatial learning and memory in APP/PS1 mice, and diminished amyloid-β accumulation.
After 12 weeks of treatment, significant cognitive enhancements were observed, correlating with increased autophagy markers.
Eighteen-month-old APP/PS1 mice received PF-04691502, showing improved outcomes compared to untreated groups.
These findings indicate that targeting the mTOR pathway may be an effective strategy for treating Alzheimer's disease.